Free Trial

Lyell Immunopharma (LYEL) SEC Filings & 10K Form

Lyell Immunopharma logo
$0.70 +0.04 (+6.17%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.61%)
As of 02/21/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Lyell Immunopharma SEC Filings

DateFilerForm TypeView
02/05/2025
12:23 PM
BlackRock, Inc. (Filed by)
Lyell Immunopharma (Subject)
Form SCHEDULE 13G/A
01/24/2025
3:39 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/10/2025
8:10 AM
Lyell Immunopharma (Filer)
Form 8-K/A
12/09/2024
8:03 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/09/2024
7:39 AM
Lyell Immunopharma (Filer)
Form 424B5
12/05/2024
11:15 PM
Lyell Immunopharma (Filer)
Form EFFECT
11/29/2024
3:19 PM
Lyell Immunopharma (Filer)
Form S-3
Registration statement under Securities Act of 1933  
11/26/2024
3:05 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
12:30 PM
Lyell Immunopharma (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
11/01/2024
3:54 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/01/2024
3:56 PM
Lyell Immunopharma (Issuer)
Ramachandra Sumant (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2024
5:00 PM
Foresite Capital Fund IV, L.P. (Filed by)
Lyell Immunopharma (Subject)
Form SC 13G
10/31/2024
3:45 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2024
3:06 PM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/26/2024
7:32 AM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
3:41 PM
Lyell Immunopharma (Issuer)
NELSEN ROBERT (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/06/2024
7:03 AM
Lyell Immunopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2024
7:06 AM
Lyell Immunopharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/06/2024
7:12 AM
Lyell Immunopharma (Filer)
Form 424B5
05/05/2024
11:15 PM
Lyell Immunopharma (Filer)
Form EFFECT
04/22/2024
3:15 PM
Lyell Immunopharma (Filer)
Form DEF 14A
04/22/2024
3:16 PM
Lyell Immunopharma (Filer)
Form DEFA14A
04/22/2024
3:17 PM
Lyell Immunopharma (Filer)
Form ARS
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LYEL) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners